BTK and hypertensive disorder: Various potential mechanisms have been suggested to play a role in the exacerbation or onset of hypertension linked to BTK inhibitors, specifically ibrutinib and acalabrutinib: inhibition of the PI3K pathway leading to vascular tissue fibrosis [156] and down-regulation of nitric oxide formation in bone marrow-derived dendritic cells, resulting in dysregulation of vascular tone [157].